​

Palvella Therapeutics (PVLA) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

PVLA Stock Forecast

Palvella Therapeutics (PVLA) stock forecast, based on 10 Wall Street analysts, predicts a 12-month average price target of $203.92, with a high of $255.00 and a low of $143.00. This represents a 64.21% increase from the last price of $124.18.

PVLA Stock Rating

Palvella Therapeutics stock's rating consensus is Buy, based on 10 Wall Street analysts. The breakdown includes 1 Strong Buy (10.00%), 9 Buy (90.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 10 0 9 1 Strong Sell Sell Hold Buy Strong Buy

PVLA Price Target Upside V Benchmarks

TypeNameUpside
StockPalvella Therapeutics64.21%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts-429
Avg Price Target-$231.25$158.17
Last Closing Price$124.18$124.18$124.18
Upside/Downside-86.22%27.37%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 26-15---15
Mar, 26-15---15
Feb, 26-15---15
Jan, 26-14---14
Dec, 25-12---12
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Feb 24, 2026Truist Financial$210.00$120.4174.40%69.11%
Feb 24, 2026Chardan Capital$210.00$118.6177.05%69.11%
Feb 24, 2026Stifel Nicolaus$250.00$119.26109.63%101.32%
Feb 24, 2026H.C. Wainwright$255.00$116.66118.58%105.35%
Jan 07, 2026Mizuho Securities$205.00$90.43126.69%65.08%
Dec 16, 2025Whitney IjemCanaccord Genuity$204.00$88.42130.72%64.28%
Dec 16, 2025Ryan DeschnerRaymond James$193.00$91.51110.91%55.42%
Dec 15, 2025Chardan Capital$174.00$88.4296.79%40.12%
Dec 15, 2025Jeff MukherjeeBTIG$192.00$88.42117.15%54.61%
Dec 15, 2025Truist Financial$190.00$88.89113.75%53.00%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Mar 24, 2026H.C. WainwrightBuyBuyhold
Feb 24, 2026H.C. WainwrightBuyBuyhold
Feb 02, 2026Cowen & Co.BuyBuyhold
Dec 16, 2025Cowen & Co.BuyBuyhold
Dec 16, 2025Raymond JamesStrong BuyStrong Buyhold
Dec 15, 2025BTIGBuyBuyhold
Dec 15, 2025UBSBuyBuyhold
Dec 15, 2025Cantor FitzgeraldOverweightOverweighthold
Dec 15, 2025OppenheimerOutperformOutperformhold
Dec 11, 2025H.C. WainwrightBuyBuyhold

Financial Forecast

EPS Forecast

$-15 $-12 $-9 $-6 $-3 $0 Dec 24 Dec 25 Dec 26 Dec 27
Dec 24Dec 25Dec 26Dec 27
Reported$-7.83$-3.71--
Avg Forecast$-3.70$-2.77$-5.41$-2.81
High Forecast$-3.02$-1.60$-1.48$-1.37
Low Forecast$-4.37$-3.93$-12.67$-4.16
Surprise %111.62%33.94%--

Revenue Forecast

Dec 24 Dec 25 Dec 26 Dec 27
Dec 24Dec 25Dec 26Dec 27
Reported----
Avg Forecast$50.00K--$5.62M
High Forecast$50.00K--$5.62M
Low Forecast$50.00K--$5.62M
Surprise %----

Net Income Forecast

$-45M $-36M $-27M $-18M $-9M $0 Dec 24 Dec 25 Dec 26 Dec 27
Dec 24Dec 25Dec 26Dec 27
Reported$-17.43M$-41.72M--
Avg Forecast$-8.22M$-6.15M$-15.75M$-6.15M
High Forecast$-6.72M$-3.56M$-3.29M$-3.05M
Low Forecast$-9.73M$-8.75M$-28.20M$-9.26M
Surprise %111.97%577.77%--

PVLA Forecast FAQ

Is Palvella Therapeutics stock a buy?

Palvella Therapeutics stock has a consensus rating of Buy, based on 10 Wall Street analysts. The rating breakdown includes 1 Strong Buy, 9 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Palvella Therapeutics is a favorable investment for most analysts.

What is Palvella Therapeutics's price target?

Palvella Therapeutics's price target, set by 10 Wall Street analysts, averages $203.92 over the next 12 months. The price target range spans from $143 at the low end to $255 at the high end, suggesting a potential 64.21% change from the previous closing price of $124.18.

How does Palvella Therapeutics stock forecast compare to its benchmarks?

Palvella Therapeutics's stock forecast shows a 64.21% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Palvella Therapeutics over the past three months?

  • April 2026: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • March 2026: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • February 2026: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Palvella Therapeutics’s EPS forecast?

Palvella Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $-5.41, marking a 45.82% increase from the reported $-3.71 in 2025. Estimates for the following years are.

What is Palvella Therapeutics’s revenue forecast?

Palvella Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $0, reflecting a 0% decrease from the reported $0 in 2025. The forecast for.

What is Palvella Therapeutics’s net income forecast?

Palvella Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $-15.748M, representing a -62.25% decrease from the reported $-41.715M in 2025. Projections indicate .